CLAIMS

1. A liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm, and the polydispersity index of the particle size distribution is 0.2 or less.

2. The liposome preparation according to claim 1, wherein the average particle size is 92.9 to 101.0 nm.

3. The liposome preparation according to claim 1 or 2, wherein the polydispersity index of the particle size distribution is 0.133 or less.

4. The liposome preparation according to any one of claims 1 to 3, wherein the number of liposomes having a particle size of less than 50 nm is 10% or less of the total population of liposomes.

5. The liposome preparation according to any one of claims 1 to 4, wherein the number of liposomes with a particle size of more than 450 nm is 10% or less of the total population of liposomes.

6. The liposome preparation according to any one of claims 1 to 5, wherein the average particle size is maintained at 90 to 110 nm for at least 1 month under the conditions of a temperature of 25°C and a relative humidity of 60% RH.

7. The liposome preparation according to any one of claims 1 to 6, wherein the CD1d ligand compound is α-galactosylceramide.

8. The liposome preparation according to claim 7, wherein the α-galactosylceramide is (2S,3S,4R)-1-o-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol.

9. The liposome preparation according to any one of claims 1 to 8, wherein the population of liposomes is contained as a liposome suspension.

10. The liposome preparation according to claim 9, wherein the pH of the liposome suspension is 5.8 to 6.8.

11. The liposome preparation according to any one of claims 1 to 8, wherein the population of liposomes is contained as a lyophilized product.

12. The liposome preparation according to any one of claims 1 to 11, which is for injection administration.

13. The liposome preparation according to any one of claims 1 to 12 for use in the prevention or treatment of graft-versus-host disease.

14. The liposome preparation according to claim 13, wherein the graft-versus-host disease is caused by allogeneic hematopoietic stem cell transplantation.

15. The liposome preparation according to any one of claims 1 to 12 for use in the prevention or treatment of organ transplant rejection.

16. The liposome preparation according to claim 15, wherein the organ transplant is a transplant of an allogeneic organ or cell.

17. The liposome preparation according to claim 15, wherein the organ transplant is a transplant of a xenogeneic organ or cell.

18. Use of the liposome preparation according to any one of claims 1 to 12 in the manufacture of a medicament for the prevention or treatment of graft-versus-host disease.

19. The use according to claim 18, wherein the graft-versus-host disease is caused by allogeneic hematopoietic stem cell transplantation.

20. Use of the liposome preparation according to any one of claims 1 to 12 in the manufacture of a medicament for the prevention or treatment of organ transplant rejection.

21. The use according to claim 20, wherein the organ transplant is a transplant of an allogeneic organ or cell.

22. The use according to claim 20, wherein the organ transplant is a transplant of a xenogeneic organ or cell.